Soluble Guanylate Cyclase Stimulators in Heart Failure

被引：12

作者：

Kansakar, Sajog ^{[1
]}

Guragain, Ashish ^{[1
]}

Verma, Deepak ^{[2
]}

Sharma, Prabhat ^{[1
,3
]}

Dhungana, Bibek ^{[4
]}

Bhattarai, Bidit ^{[5
]}

Yadav, Sunil ^{[6
]}

Gautam, Ishant ^{[7
]}

机构：

[1] Manipal Coll Med Sci, Internal Med, Pokhara, Nepal

[2] Calif Inst Behav Neurosci & Psychol, Internal Med Family Med, Fairfield, CA USA

[3] Shankarapur Hosp, Internal Med, Kathmandu, Nepal

[4] KIST Med Coll, Internal Med, Lalitpur, Nepal

[5] Venus Hosp, Internal Med, Kathmandu, Nepal

[6] Topa Primary Hlth Ctr, Internal Med, Rajbiraj, Nepal

[7] Bhaktapur Hosp, Internal Med, Bhaktapur, Nepal

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 09期

关键词：

heart failure with reduced ejection fraction (hfref); heart failure with preserved ejection fraction (hfpef); heart failure; guanylate cyclase stimulators; vericiguat; PRESERVED EJECTION FRACTION; NITRIC-OXIDE; VERICIGUAT; PATHOPHYSIOLOGY; CAPACITY; PLACEBO;

D O I：

10.7759/cureus.17781

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure has a high global burden of morbidity and mortality. Despite significant advances in medical management of heart failure, the prognosis remains poor. This justifies the search for newer therapeutic agents. Recently, soluble guanylate stimulators have demonstrated favorable results in clinical trials. This article aims to summarize the guanylate cyclase signaling pathway, the role of soluble guanylate cyclase stimulators in heart failure, and data from recent clinical trials of these drugs. We concluded that soluble guanylate cyclase stimulators have significant benefits in reducing hospitalizations in patients with heart failure with reduced ejection fraction that are at high risk of cardiovascular events. There appears to be no benefit of these drugs in patients with heart failure with preserved ejection fraction.

引用

页数：7

共 50 条

[31] Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go? [J].

Xiao, Sijia ;

Li, Qianbin ;

Hu, Liqing ;

Yu, Zutao ;

Yang, Jie ;

Chang, Qi ;

Chen, Zhuo ;

Hu, Gaoyun .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 19 (18) :1544-1557

[32] Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021 [J].

Jia, Xiao-Yan ;

Liu, Yong-Ming ;

Wang, Yong-Fei ;

An, Jin-Yang ;

Peng, Ke-Ling ;

Wang, Hua .

FRONTIERS IN PHARMACOLOGY, 2022, 13

[33] Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) [J].

Pieske, Burkert ;

Butler, Javed ;

Filippatos, Gerasimos ;

Lam, Carolyn ;

Maggioni, Aldo Pietro ;

Ponikowski, Piotr ;

Shah, Sanjiv ;

Solomon, Scott ;

Kraigher-Krainer, Elisabeth ;

Samano, Eliana Tibana ;

Scalise, Andrea Viviana ;

Mueller, Katharina ;

Roessig, Lothar ;

Gheorghiade, Mihai .

EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (09) :1026-1038

[34] Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure [J].

Boerrigter, Guido ;

Costello-Boerrigter, Lisa C. ;

Cataliotti, Alessandro ;

Lapp, Harald ;

Stasch, Johannes-Peter ;

Burnett, John C., Jr. .

HYPERTENSION, 2007, 49 (05) :1128-1133

[35] Guanylate cyclase stimulators for pulmonary hypertension [J].

Wardle, Andrew J. ;

Seager, Matthew J. ;

Wardle, Richard ;

Tulloh, Robert M. R. ;

Gibbs, J. Simon R. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (08)

[36] Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947 [J].

Brockunier, Linda ;

Stelmach, John ;

Guo, Jian ;

Spencer, Tracy ;

Rosauer, Keith ;

Bansal, Alka ;

Cai, Sheng-Jian ;

Chen, Nancy ;

Cummings, John ;

Huang, Li ;

Johnson, Timothy ;

Levesque, Sonia ;

Luo, Lin ;

Maloney, Kevin ;

Metzger, Joseph ;

Mortko, Christopher ;

Ortega, Karen ;

Pai, Lee-Yuh ;

Pereira, Antonio ;

Salituro, Gino ;

Shang, Jackie ;

Shepherd, Cherrie ;

Xu, Shiyao Sherrie ;

Yang, Qifeng ;

Cui, Jisong ;

Roy, Sophie ;

Parmee, Emma ;

Raghavan, Subharekha .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (21)

[37] Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern [J].

Michelakis, E. D. .

EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (04) :717-721

[38] Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF) [J].

Xia, Juan ;

Hui, Nan ;

Tian, Lei ;

Liang, Chengyuan ;

Zhang, Jie ;

Liu, Jifang ;

Wang, Jun ;

Ren, Xiaodong ;

Xie, Xiaolin ;

Wang, Kun .

BIOMEDICINE & PHARMACOTHERAPY, 2022, 149

[39] Soluble Guanylate Cyclase Not a Dull Enzyme [J].

Boerrigter, Guido ;

Burnett, John C., Jr. .

CIRCULATION, 2009, 119 (21) :2752-2754

[40] Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure [J].

Follmann, Markus ;

Ackerstaff, Jens ;

Redlich, Gorden ;

Wunder, Frank ;

Lang, Dieter ;

Kern, Armin ;

Fey, Peter ;

Griebenow, Nils ;

Kroh, Walter ;

Becker-Pelster, Eva-Maria ;

Kretschmer, Axel ;

Geiss, Volker ;

Li, Volkhart ;

Straub, Alexander ;

Mittendorf, Joachim ;

Jautelat, Rolf ;

Schirok, Hartmut ;

Schlemmer, Karl-Heinz ;

Lustig, Klemens ;

Gerisch, Michael ;

Knorr, Andreas ;

Tine, Hanna ;

Mondritzki, Thomas ;

Truebel, Hubert ;

Sandner, Peter ;

Stasch, Johannes-Peter .

JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (12) :5146-5161

← 1 2 3 4 5 →